Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of innovative pharmaceutical products for the treatment of orphan neuromuscular diseases. Santhera currently has three compounds in seven clinical-stage development programs.
Santhera's vision is to become a leading specialty pharmaceutical company offering therapies for a number of indications in this area of high unmet medical need which includes many orphan indications with no current therapy.
The World Orphan Drug Congress is a multi-faceted event
|
You may also like to attend:
See more › |